Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
2.6K
Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

62
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
62
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nongenetic engineering nanozyme proximity labeling reveals subcellular in situ interactomes and trafficking pathways of nanoparticles.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Estimated Cardiorespiratory Fitness and Risk of Incident Frailty in Middle-Aged and Older Adults: A Cross-National Longitudinal Cohort Study.

Healthcare (Basel, Switzerland)·2026
Same author

MYC-bound enhancer RNAs in cis regulate gene transcription and tumorigenesis.

Science advances·2026
Same author

Catalytic ROS-Amplifying Self-Immolative Linkers Enable Carrier-Free Prodrugs for Refractory Tumors.

Angewandte Chemie (International ed. in English)·2026
Same author

Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy.

Nature nanotechnology·2026
Same author

Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma.

Theranostics·2026

Related Experiment Video

Updated: Jun 5, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K

YAP/TAZ Inhibitor-Based Drug Delivery System for Selective Tumor Accumulation and Cancer Combination Therapy.

Ziqian Zhang1, Zhangyi Luo1, Haozhe Huang1

  • 1Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.

Biomacromolecules
|December 7, 2024
PubMed
Summary

Researchers developed novel prodrug polymers to improve the delivery of niflumic acid (NA), a YAP/TAZ inhibitor. This nanocombination therapy effectively enhanced breast cancer treatment by targeting tumors and inhibiting growth.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K

Related Experiment Videos

Last Updated: Jun 5, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.5K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K

Area of Science:

  • Oncology
  • Materials Science
  • Nanotechnology

Background:

  • Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key drivers in cancer development and therapy resistance.
  • Pharmacological inhibition of YAP/TAZ is a promising strategy for cancer treatment.
  • Niflumic acid (NA), a YAP/TAZ inhibitor, has limited clinical utility due to poor in vivo half-life.

Purpose of the Study:

  • To develop improved prodrug strategies for YAP/TAZ inhibition.
  • To create self-assembled nanoparticles for enhanced delivery of niflumic acid.
  • To investigate a nanocombination therapy for breast cancer treatment.

Main Methods:

  • Synthesized a series of niflumic acid-based prodrug polymers.
  • Investigated physicochemical properties of self-assembled nanoparticles.
  • Utilized optimal prodrug polymer as a micellar nanocarrier for receptor tyrosine kinase inhibitors (RTKIs).

Main Results:

  • Developed prodrug polymers that self-assemble into nanoparticles, improving niflumic acid bioavailability.
  • The optimal prodrug nanocarrier selectively accumulated in tumors.
  • Combination therapy with RTKIs (e.g., Dasatinib) synergistically inhibited tumor growth.

Conclusions:

  • Prodrug polymer nanoparticles offer a viable strategy to overcome niflumic acid's limitations.
  • Nanocombination therapy demonstrates enhanced efficacy in preclinical breast cancer models.
  • This approach holds potential for improved cancer treatment strategies.